Multiple Sclerosis
Built on real world patient insights, Ekiva-MS addresses the unmet needs of those living with multiple sclerosis, providing support to help manage their disease and treatment journey.
MS is an unpredictable disease, with every patient experiencing symptoms and severity differently. This poses ongoing challenges for HCPs when determining a treatment plan and patients can feel a lack of control over their own disease and how to manage it.
We always take a patient-first approach to creating any product. With our discovery process uncovering key insights, we closely collaborated with patients and our customer, Novartis, to ensure the app supports MS patients.
Ekiva-MS includes symptom tracking, in-app functionality test, educational content and personalized reports. An app paving the way in the future of patient empowerment, we deliver our solutions to patients at speed, with Ekiva-MS being launched in 6 months.
Every patient experiences different MS symptoms, meaning their treatment plan must be highly personalized if the best care is to be given. For this, historical information around the patient’s symptoms and their disease progression over time is valuable. Within this, many patients face the problem of a lack of sufficient face time with their HCP. Often seeing them only once a year for a short consultation, these talks can lack the data and objectivity of symptom progression needed to provide the best care. Patients can feel alone in their disease management and having to remember any changes they have experienced over a year is an overwhelming prospect.
The Dawn Discovery is a process that enables us to be confident that our products always centre around the patient and addressing their biggest challenges and unmet needs. Co-creation through user testing, interviews and ongoing feedback means that we could directly understand what they would want in a companion app to empower and support them in their day-to-day.
Through user research and our design team’s expert knowledge, we determined which features were key to be the most useful for patients in managing their disease, as well as encouraging them to feel supported and empowered to have better, data-driven conversations with their HCP.
To deliver true patient empowerment, the app needed to fit into people’s daily lives without friction and be easy to use as a part of their disease management. Ekiva-MS includes a number of features to support the user.
Symptom logging, mood tracking, informative articles, functionality tests and exporting their logs into personal reports are all within the patient companion app, encouraging patients to share key information and experiences that can empower them in their day-to-day and HCP conversations.
We delivered Ekiva-MS to its first market, Germany, in only 6 months, with over 2,000 downloads in the first 8 weeks of launch, highlighting the need for such a product. The Dawn Platform enables us to deliver products to market in such a short time through pre-built concepts, regulatory documentation ready to go and expert teams building products in collaboration with our pharma partners.
The Dawn Discovery is a process that enables us to be confident that our products always centre around the patient and addressing their biggest challenges and unmet needs. Co-creation through user testing, interviews and ongoing feedback means that we could directly understand what they would want in a companion app to empower and support them in their day-to-day.
Through user research and our design team’s expert knowledge, we determined which features were key to be the most useful for patients in managing their disease, as well as encouraging them to feel supported and empowered to have better, data-driven conversations with their HCP.
The content on this page is for informational purposes only and is not intended to provide any medical advice. Please consult a medical professional for any information. The information on this page is not tailored to country-specific requirements. The images depict models secured with correct rights and not real patients. Additional disclaimers may apply in accordance with the Terms of Use. DHDK_WEB_EKVMS_003_V0
Copenhagen
New York
Zürich